AU Patent

AU2020233714A1 — Methods for treating Arenaviridae and Coronaviridae virus infections

Assigned to Gilead Sciences Inc · Expires 2020-10-08 · 6y expired

What this patent protects

OF THE DISCLOSURE Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: R8 R10 R 7 N 0 ' O- O N NR9 R3 R 2 wherein the ' position of the nucleoside sugar is substituted. The comp…

USPTO Abstract

OF THE DISCLOSURE Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: R8 R10 R 7 N 0 ' O- O N NR9 R3 R 2 wherein the ' position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020233714A1
Jurisdiction
AU
Classification
—
Expires
2020-10-08
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.